TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
Healthcare
$2.18 +0.49%
+$0.02 today
- Market cap
- $134.20M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
52W Low $2.20High $7.95
Volume 0.36M
Average 0.38M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$18.01M
FY 2025 · Annual
Investing Cash Flow
-$838,000.00
FY 2025 · Annual
Financing Cash Flow
$30.76M
FY 2025 · Annual
-18.9% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (28.85M) | (47.19M) | (59.36M) | (30.05M) | (39.23M) |
| Depreciation & Amortization | 464K | 398K | 684K | 744K | 626K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 109K | 368K | 1.4M | 5.44M | 9.13M |
| Change in Working Capital | (131K) | 2.3M | 537K | (9.55M) | 2.07M |
| Accounts Receivables | (741K) | (200K) | (1.98M) | (1.72M) | (1.63M) |
| Inventory | (725K) | (179K) | (1.07M) | (1.5M) | 971K |
| Accounts Payables | 3.18M | 5.25M | 2.84M | (4.38M) | 2.02M |
| Other Working Capital | (1.84M) | (2.57M) | 751K | (1.94M) | 711K |
| Other Non-Cash Items | 5.71M | 11.81M | 6.16M | (7.43M) | 9.39M |
| Operating Cash Flow | (22.7M) | (32.31M) | (50.58M) | (40.84M) | (18.01M) |
| Capital Expenditures | (1.26M) | (786K) | (588K) | (345K) | (918K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 80K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1.16M) | (1.13M) | (1M) | 0 | 0 |
| Investing Cash Flow | (2.26M) | (1.79M) | (1.59M) | (345K) | (838K) |
| Debt Repayment | (1.3M) | (131K) | (87K) | 24.92M | 9.92M |
| Common Stock Issued | 0 | 0 | 0 | 15.54M | 22.91M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 54K | 94K | 45.53M | (2.52M) | (2.07M) |
| Financing Cash Flow | 50.77M | 13.46M | 54.63M | 37.94M | 30.76M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.81M | (20.64M) | 2.46M | (3.25M) | 11.91M |
| Free Cash Flow | (23.96M) | (33.1M) | (51.17M) | (41.19M) | (18.93M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$39.2M
+ D&A$626.0K
+ Stock-Based Comp$9.1M
+ Deferred Tax$0
+ Working Capital$2.1M
+ Other Non-Cash$9.4M
= Operating Cash Flow-$18.0M
- Capex-$918.0K
= Free Cash Flow-$18.9M
Analysis
FY2025 free cash flow is -$18.9M. FCF conversion is 48.3% of net income. Operating cash flow was -$18.0M, with capex of -$918.0K. The largest bridge item is Other Non-Cash at $9.4M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 7, 2026 |
Does TLSI generate free cash flow?
TriSalus Life Sciences, Inc. (TLSI) generated -$18.93M of free cash flow in fiscal 2025.
How much operating cash flow does TLSI produce?
Operating cash flow was -$18.01M, before capital expenditures of $918,000.00.
Continue the stock analysis
Jump to another research area for this company.